Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETON NASDAQ:KPTI NASDAQ:MGTX NASDAQ:PURR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETONEton Pharmaceuticals$29.63-0.7%$23.17$13.09▼$32.31$810.54M0.82345,336 shs67,145 shsKPTIKaryopharm Therapeutics$8.79-0.2%$7.94$3.65▼$10.99$197.90M0.8813,276 shs82,990 shsMGTXMeiraGTx$9.70-2.0%$8.69$4.55▼$11.85$901.63M1.23596,049 shs110,646 shsPURRHyperliquid Strategies$6.07-7.0%$5.63$3.01▼$7.09$753.12M1.444.67 million shs2.79 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETONEton Pharmaceuticals+0.64%+3.25%+13.20%+96.19%+76.88%KPTIKaryopharm Therapeutics+1.97%+0.46%+10.13%+33.89%+46.59%MGTXMeiraGTx+0.81%+5.21%+10.37%+31.65%+80.66%PURRHyperliquid Strategies-2.68%+4.15%+8.65%+41.04%+652,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETONEton Pharmaceuticals$29.63-0.7%$23.17$13.09▼$32.31$810.54M0.82345,336 shs67,145 shsKPTIKaryopharm Therapeutics$8.79-0.2%$7.94$3.65▼$10.99$197.90M0.8813,276 shs82,990 shsMGTXMeiraGTx$9.70-2.0%$8.69$4.55▼$11.85$901.63M1.23596,049 shs110,646 shsPURRHyperliquid Strategies$6.07-7.0%$5.63$3.01▼$7.09$753.12M1.444.67 million shs2.79 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETONEton Pharmaceuticals+0.64%+3.25%+13.20%+96.19%+76.88%KPTIKaryopharm Therapeutics+1.97%+0.46%+10.13%+33.89%+46.59%MGTXMeiraGTx+0.81%+5.21%+10.37%+31.65%+80.66%PURRHyperliquid Strategies-2.68%+4.15%+8.65%+41.04%+652,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETONEton Pharmaceuticals 2.40Hold$39.3332.91% UpsideKPTIKaryopharm Therapeutics 2.88Moderate Buy$16.1481.79% UpsideMGTXMeiraGTx 2.75Moderate Buy$25.67162.15% UpsidePURRHyperliquid Strategies 2.50Moderate Buy$8.8243.06% UpsideCurrent Analyst Ratings BreakdownLatest KPTI, ETON, PURR, and MGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026PURRHyperliquid Strategies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$6.00 ➝ $8.005/6/2026KPTIKaryopharm Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $13.004/27/2026KPTIKaryopharm Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$8.00 ➝ $16.004/24/2026PURRHyperliquid Strategies Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.004/22/2026MGTXMeiraGTx Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$26.00 ➝ $30.004/21/2026ETONEton Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026MGTXMeiraGTx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026ETONEton Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/17/2026MGTXMeiraGTx Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$16.00 ➝ $24.004/9/2026PURRHyperliquid Strategies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/30/2026KPTIKaryopharm Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$12.00 ➝ $8.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETONEton Pharmaceuticals$79.95M10.13N/AN/A$0.98 per share30.20KPTIKaryopharm Therapeutics$146.07M1.37N/AN/A($16.00) per share-0.56MGTXMeiraGTx$81.39M11.14N/AN/A($0.07) per share-139.87PURRHyperliquid Strategies$1M764.03N/AN/A$1.52 per share4.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETONEton Pharmaceuticals-$4.60M-$0.18N/A16.26N/A-5.75%-2.60%-0.66%5/14/2026 (Estimated)KPTIKaryopharm Therapeutics-$196.04M-$16.62N/AN/AN/A-134.21%N/A-122.29%5/14/2026 (Estimated)MGTXMeiraGTx-$114.20M-$1.42N/AN/AN/A-140.31%-1,065.47%-53.33%5/12/2026 (Estimated)PURRHyperliquid Strategies-$16.01M-$9.27N/A2.04N/AN/A-94.51%-89.13%N/ALatest KPTI, ETON, PURR, and MGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ETONEton Pharmaceuticals$0.10N/AN/AN/A$22.31 millionN/A5/14/2026Q1 2026KPTIKaryopharm Therapeutics-$1.45N/AN/AN/A$31.40 millionN/A5/12/2026Q1 2026MGTXMeiraGTx-$0.43N/AN/AN/A$17.00 millionN/A3/26/2026Q4 2025MGTXMeiraGTx-$0.60$0.19+$0.79$0.19$3.87 million$75.36 million3/19/2026Q4 2025ETONEton Pharmaceuticals$0.12$0.05-$0.07$0.05$20.58 million$21.28 million2/13/2026Q4 2025KPTIKaryopharm Therapeutics-$2.26-$2.23+$0.03-$5.71$33.16 million$34.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthETONEton PharmaceuticalsN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/APURRHyperliquid StrategiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETONEton Pharmaceuticals0.831.571.17KPTIKaryopharm TherapeuticsN/A1.121.08MGTXMeiraGTxN/A0.750.75PURRHyperliquid StrategiesN/A31.6231.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETONEton Pharmaceuticals27.86%KPTIKaryopharm Therapeutics66.44%MGTXMeiraGTx67.48%PURRHyperliquid Strategies9.45%Insider OwnershipCompanyInsider OwnershipETONEton Pharmaceuticals16.49%KPTIKaryopharm Therapeutics1.68%MGTXMeiraGTx7.50%PURRHyperliquid Strategies8.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETONEton Pharmaceuticals2027.36 million22.85 millionOptionableKPTIKaryopharm Therapeutics38022.55 million22.17 millionOptionableMGTXMeiraGTx30092.57 million85.63 millionOptionablePURRHyperliquid StrategiesN/A123.97 million113.46 millionN/AKPTI, ETON, PURR, and MGTX HeadlinesRecent News About These CompaniesHyperliquid Strategies (NASDAQ:PURR) Price Target Raised to $8.00 at Cantor FitzgeraldMay 12 at 3:57 AM | americanbankingnews.comHyperliquid Strategies (NASDAQ:PURR) Price Target Raised to $8.00May 11 at 9:06 AM | marketbeat.comWhy Hyperliquid Strategies Keeps Buying HYPE Despite a $165M Net LossMay 9 at 11:37 PM | memeburn.comMHyperliquid Strategies Q3 Earnings Call HighlightsMay 8, 2026 | marketbeat.comHyperliquid Strategies Reports $165 Million Loss as HYPE Treasury ExpandsMay 8, 2026 | financefeeds.comFHyperliquid Strategies Reports $152.5 Million Quarterly Profit as HYPE Rally Lifts TreasuryMay 8, 2026 | finance.yahoo.comHyperliquid Strategies Inc. (PURR) Stock: Shares Decline Despite Expanding HYPE Holdings and Rising Staking IncomeMay 8, 2026 | blockonomi.comHyperliquid Strategies Highlights Q3 Results, HYPE Treasury ExpansionMay 7, 2026 | tipranks.comHyperliquid Strategies (NASDAQ:PURR) Issues Earnings ResultsMay 7, 2026 | marketbeat.comHyperliquid Strategies and Unit Labs Announce Validator on HyperliquidMay 7, 2026 | prnewswire.comHyperliquid Strategies Inc Reports Financial Results for the Quarter Ended March 31, 2026May 7, 2026 | prnewswire.comHyperliquid Strategies (NASDAQ:PURR) Hits New 52-Week High - Here's What HappenedMay 6, 2026 | marketbeat.comHyperliquid Strategies Inc Announces Webcast to Discuss Results for the Fiscal Quarter Ended March 31, 2026April 28, 2026 | prnewswire.comHyperliquid Strategies (NASDAQ:PURR) Trading Up 6.9% - Time to Buy?April 27, 2026 | marketbeat.comMaxim Group initiates coverage of Hyperliquid Strategies (PURR) with buy recommendationApril 26, 2026 | msn.comMaxim Group Begins Coverage on Hyperliquid Strategies (NASDAQ:PURR)April 24, 2026 | marketbeat.comHyperliquid Strategies (NASDAQ:PURR) Shares Gap Up - Here's WhyApril 22, 2026 | marketbeat.comHyperliquid Strategies (NASDAQ:PURR) Shares Down 7.7% - Time to Sell?April 21, 2026 | marketbeat.comHyperliquid Strategies (NASDAQ:PURR) Shares Gap Down - Should You Sell?April 20, 2026 | marketbeat.comHyperliquid Strategies (NASDAQ:PURR) Reaches New 12-Month High - Still a Buy?April 14, 2026 | marketbeat.comHyperliquid Strategies Target of Unusually Large Options Trading (NASDAQ:PURR)April 13, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKPTI, ETON, PURR, and MGTX Company DescriptionsEton Pharmaceuticals NASDAQ:ETON$29.62 -0.22 (-0.72%) As of 12:49 PM Eastern This is a fair market value price provided by Massive. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Karyopharm Therapeutics NASDAQ:KPTI$8.79 -0.02 (-0.24%) As of 12:49 PM Eastern This is a fair market value price provided by Massive. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.MeiraGTx NASDAQ:MGTX$9.70 -0.20 (-2.00%) As of 12:50 PM Eastern This is a fair market value price provided by Massive. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Hyperliquid Strategies NASDAQ:PURR$6.07 -0.46 (-6.98%) As of 12:49 PM Eastern This is a fair market value price provided by Massive. Learn more.Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc., is based in NEW YORK. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
